Innovative Dosing Approaches To Maximise Bacterial Killing And Prevent Resistance In Septic Critically Ill Patients.
Funder
National Health and Medical Research Council
Funding Amount
$830,364.00
Summary
Patients in the intensive care unit (ICU) frequently die from infection. It remains unknown how important antibiotic dose optimisation is for these patients and whether it may enable more effective treatment. In this project, we propose to compare existing approaches to antibiotic dosing in ICU patients with innovative alternatives. We will determine which dosing approach results in better antibacterial efficacy and reduce the development of antibiotic resistance.
Improving Dosing Of Common Antibiotics Used In Critically Ill Australian Indigenous Patients
Funder
National Health and Medical Research Council
Funding Amount
$98,148.00
Summary
Optimal antibiotic dosing in patients in the intensive care unit saves lives. However, the way antibiotics move through the body of an intensive care unit patient can be different to other patients. Therefore, research that identifies specific dosing for these patients is essential. Further to this, no research in an Indigenous population is available. The aim of this research is to address this gap by developing optimal antibiotic doses for Indigenous Australians in the intensive care unit.
Novel Octapeptin Antibiotics Targeting Extremely Drug Resistant 'superbugs'
Funder
National Health and Medical Research Council
Funding Amount
$946,024.00
Summary
The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health. Many clinicians worldwide have already been confronted with the reality of infections caused by extremely drug resistant (XDR) bacterial 'superbugs' resistant to all available antibiotics. This project aims to develop safe and efficacious octapeptin antibiotics for the treatment of life-threatening infections caused by problematic XDR ‘superbugs'.
The Hunt For New-generation Lipopeptide Antibiotics Targeting Gram-negative ‘Superbugs’
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
The dry antibiotic discovery and development pipeline, together with the increasing incidence of bacterial resistance in the clinic has been dubbed ‘the perfect storm’. This project involves the design, synthesis and preclinical evaluation of a new generation of polymyxin-like lipopeptides that have low nephrotoxicity and specifically target polymyxin-resistant Gram-negative ‘superbugs’.